title: The role of p53 in combination radioimmunotherapy with 64Cu-DOTA-cetuximab and cisplatin in a mouse model of colorectal cancer.
abstract: Radioimmunotherapy has been successfully used in the treatment of lymphoma but thus far has not demonstrated significant efficacy in humans beyond disease stabilization in solid tumors. Radioimmunotherapy with (64)Cu was highly effective in a hamster model of colorectal cancer, but targeted radiotherapies with this radionuclide have since not shown as much success. It is widely known that mutations in key proteins play a role in the success or failure of cancer therapies. For example, the KRAS mutation is predictive of poor response to anti-epidermal growth factor receptor therapies in colorectal cancer, whereas p53 is frequently mutated in tumors, causing resistance to multiple therapeutic regimens.
  
  
  METHODS
  We previously showed that nuclear localization of (64)Cu-labeled DOTA-cetuximab was enhanced in p53 wild-type tumor cells. Here, we examine the role of p53 in the response to radioimmunotherapy with (64)Cu-DOTA-cetuximab in KRAS-mutated HCT116 tumor-bearing mice, with and without cisplatin, which upregulates wild-type p53.
  
  
  RESULTS
  Experiments with HCT116 cells that are p53 +/+ (p53 wild-type) and -/- (p53 null) grown in cell culture demonstrated that preincubation with cisplatin increased expression of p53 and subsequently enhanced localization of (64)Cu from (64)Cu-acetate and (64)Cu-DOTA-cetuximab to the tumor cell nuclei. Radioimmunotherapy studies in p53-positive HCT116 tumor-bearing mice, receiving either radioimmunotherapy alone or in combination with cisplatin, showed significantly longer survival in mice receiving unlabeled cetuximab or cisplatin alone or in combination (all, P < 0.01). In contrast, the p53-negative tumor-bearing mice treated with radioimmunotherapy alone or combined with cisplatin showed no survival advantage, compared with control groups (all, P > 0.05).
  
  
  CONCLUSIONS
  Together, these data suggest that (64)Cu specifically delivered to epidermal growth factor receptor-positive tumors by cetuximab can suppress tumor growth despite the KRAS status and present opportunities for personalized clinical treatment strategies in colorectal cancer.
authors.affiliation: Mallinckrodt Institute of Radiology, Washington University, St. Louis, Missouri, USA.
authors.forename: Yunjun
authors.initials: Y
authors.lastname: Guo
authors.forename: Jesse J
authors.initials: JJ
authors.lastname: Parry
authors.forename: Richard
authors.initials: R
authors.lastname: Laforest
authors.forename: Buck E
authors.initials: BE
authors.lastname: Rogers
authors.forename: Carolyn J
authors.initials: CJ
authors.lastname: Anderson
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage; D045744:Cell Line, Tumor; D000068818:Cetuximab; D002945:Cisplatin / Q000008:administration & dosage*; D015179:Colorectal Neoplasms / Q000175:diagnosis / Q000276:immunology* / Q000628:therapy*; D003131:Combined Modality Therapy / Q000379:methods; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D009942:Organometallic Compounds / Q000008:administration & dosage*; D016499:Radioimmunotherapy / Q000379:methods*; D019275:Radiopharmaceuticals; D016896:Treatment Outcome; D016159:Tumor Suppressor Protein p53 / Q000276:immunology*
chemical_list: C532429:64Cu-DOTA-cetuximab; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D009942:Organometallic Compounds; D019275:Radiopharmaceuticals; D016159:Tumor Suppressor Protein p53; D000068818:Cetuximab; D002945:Cisplatin
keywords: 64Cu; KRAS mutation; colorectal cancer; radioimmunotherapy